DC Field | Value | Language |
---|---|---|
dc.contributor.author | E Kim | - |
dc.contributor.author | Eun Kyung Lim | - |
dc.contributor.author | G Park | - |
dc.contributor.author | C Park | - |
dc.contributor.author | J W Lim | - |
dc.contributor.author | H Lee | - |
dc.contributor.author | W Na | - |
dc.contributor.author | M Yeom | - |
dc.contributor.author | J Kim | - |
dc.contributor.author | D Song | - |
dc.contributor.author | S Haam | - |
dc.date.accessioned | 2021-11-24T15:30:25Z | - |
dc.date.available | 2021-11-24T15:30:25Z | - |
dc.date.issued | 2021 | - |
dc.identifier.issn | 0935-9648 | - |
dc.identifier.uri | https://oak.kribb.re.kr/handle/201005/25049 | - |
dc.description.abstract | While the coronavirus disease (COVID-19) accounts for the current global pandemic, the emergence of other unknown pathogens, named “Disease X,” remains a serious concern in the future. Emerging or re-emerging pathogens continue to pose significant challenges to global public health. In response, the scientific community has been urged to create advanced platform technologies to meet the ever-increasing needs presented by these devastating diseases with pandemic potential. This review aims to bring new insights to allow for the application of advanced nanomaterials in future diagnostics, vaccines, and antiviral therapies, thereby addressing the challenges associated with the current preparedness strategies in clinical settings against viruses. The application of nanomaterials has advanced medicine and provided cutting-edge solutions for unmet needs. Herein, an overview of the currently available nanotechnologies is presented, highlighting the significant features that enable them to control infectious diseases, and identifying the challenges that remain to be addressed for the commercial production of nano-based products is presented. Finally, to conclude, the development of a nanomaterial-based system using a “One Health” approach is suggested. This strategy would require a transdisciplinary collaboration and communication between all stakeholders throughout the entire process spanning across research and development, as well as the preclinical, clinical, and manufacturing phases. | - |
dc.publisher | Wiley | - |
dc.title | Advanced nanomaterials for preparedness against (re-)emerging viral diseases | - |
dc.title.alternative | Advanced nanomaterials for preparedness against (re-)emerging viral diseases | - |
dc.type | Article | - |
dc.citation.title | Advanced Materials | - |
dc.citation.number | 0 | - |
dc.citation.endPage | 2005927 | - |
dc.citation.startPage | 2005927 | - |
dc.citation.volume | 33 | - |
dc.contributor.affiliatedAuthor | Eun Kyung Lim | - |
dc.contributor.alternativeName | 김은정 | - |
dc.contributor.alternativeName | 임은경 | - |
dc.contributor.alternativeName | 박근선 | - |
dc.contributor.alternativeName | 박채원 | - |
dc.contributor.alternativeName | 임종우 | - |
dc.contributor.alternativeName | 이효 | - |
dc.contributor.alternativeName | 나운성 | - |
dc.contributor.alternativeName | 염민주 | - |
dc.contributor.alternativeName | 김진영 | - |
dc.contributor.alternativeName | 송대섭 | - |
dc.contributor.alternativeName | 함승주 | - |
dc.identifier.bibliographicCitation | Advanced Materials, vol. 33, pp. 2005927-2005927 | - |
dc.identifier.doi | 10.1002/adma.202005927 | - |
dc.subject.keyword | Antiviral therapeutics | - |
dc.subject.keyword | Diagnostic tools | - |
dc.subject.keyword | Emerging viral diseases | - |
dc.subject.keyword | Nanomaterials | - |
dc.subject.keyword | Nanovaccines | - |
dc.subject.local | Antiviral therapeutics | - |
dc.subject.local | Diagnostic tools | - |
dc.subject.local | diagnostic tool | - |
dc.subject.local | Emerging viral diseases | - |
dc.subject.local | Nanomaterials | - |
dc.subject.local | nanomaterials | - |
dc.subject.local | Nanomaterial | - |
dc.subject.local | Nanovaccines | - |
dc.description.journalClass | Y | - |
There are no files associated with this item.
Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.